Related CAS #
17506-66-0 (HCl); 153-87-7 (free base)
Synonym
Oxypertine hydrochloride; Oxypertine HCl; NSC169107; NSC-169107; NSC 169107
IUPAC/Chemical Name
1H-Indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-, hydrochloride (1:1)
InChi Key
USAPVNXIZYFWLO-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H29N3O2.ClH/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18;/h4-8,15-16,24H,9-14H2,1-3H3;1H
SMILES Code
CC(N1)=C(CCN2CCN(C3=CC=CC=C3)CC2)C4=C1C=C(OC)C(OC)=C4.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
415.96
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Motohashi N, Takashima M, Mataga N, Nishikawa T, Ogawa A, Watanabe S, Toru M. Effects of sulpiride and oxypertine on the dopaminergic system in the rat striatum. Neuropsychobiology. 1992;25(1):29-33. PubMed PMID: 1351265.
2: Somohano MD, Broissin MC, Sobrino Z A. [Clinical evaluation of oxypertine in anxiety conditions]. Neurol Neurocir Psiquiatr. 1976;17(3):171-80. Spanish. PubMed PMID: 12484.
3: Moroji T, Okuyama T, Hagino Y, Sekiguchi R. Neurochemical and behavioral studies on the mode of action of oxypertine. Arzneimittelforschung. 1986 May;36(5):804-8. PubMed PMID: 2873819.
4: Miranda H. Effects of oxypertine on the isolated vas deferens of the rat. Br J Pharmacol. 1978 Apr;62(4):515-8. PubMed PMID: 26443; PubMed Central PMCID: PMC1668046.
5: Nakamura J, Uchimura N, Yamada S, Nakazawa Y. [Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol]. Nihon Shinkei Seishin Yakurigaku Zasshi. 1994 Aug;14(4):269-77. Japanese. PubMed PMID: 7975931.
6: Ogawa T, Nagao T, Kashiwabara K, Fujiwara Y, Harada T, Otsuki S. Tardive dyskinesia and neurotransmitters: effects of sodium valproate, cyproheptadine, oxypertine, hydroxyzine pamoate and Ca-hopantenate on monoamine metabolites, cyclic nucleotides and gamma-aminobutyric acid in human cerebrospinal fluid. Clin Ther. 1984;7 Spec No:1-17. PubMed PMID: 6085032.
7: Soni SD, Freeman HL, Hussein EM. Oxypertine in tardive dyskinesia: an 8-week controlled study. Br J Psychiatry. 1984 Jan;144:48-52. PubMed PMID: 6140973.
8: Akiyama K, Nagao T, Yamamoto M, Fujimoto A, Ebara T, Sato M, Otsuki S. CSF monoamine metabolism in patients with tardive dyskinesia: effect of oxypertine and hydroxyzine pamoate. Folia Psychiatr Neurol Jpn. 1983;37(2):129-35. PubMed PMID: 6200411.
9: Davie IT, Slawson KB. Oral premedication with oxypertine. Br J Anaesth. 1976 Sep;48(9):915-8. PubMed PMID: 9125.
10: CALWELL WP, JACOBSEN M, SKARBEK A. A COMPARATIVE STUDY OF OXYPERTINE AND TRIFLUOPERAZINE IN CHRONIC SCHIZOPHRENIA--A NEW APPLICATION OF THE WING RATING SCALE. Br J Psychiatry. 1964 Jul;110:520-30. PubMed PMID: 14153362.
